Antidepressant fluvoxamine may reduce risk of COVID-19 hospitalisation: Lancet study

Fluvoxamine is currently used to treat mental health conditions such as depression and obsessive-compulsive disorders. It was chosen for study as a potential treatment for COVID-19 due to its anti-inflammatory properties.